title: [Treatment of cystoid macular edema with bevacizumab in course of Irvine-Gass syndrome].
abstract: OBJECTIVE
  To determine clinical effect of intravitreal bevacizumab (Avastin) in patients with cystoid macular edema after cataract surgery.
  
  
  METHODS
  Four eyes of four patients treated with 1 intravitreal injection of 1.25 mg Avastin. In three cases duration of cystoid macular edema was less then 4 months, in one eye cystoid macular edema was chronic (more than 4 months). Visual acuity and clinical effect in spectral optical coherence tomography (central retinal thickness and fovea anatomy) was examined before and after intravitreal injection.
  
  
  RESULTS
  Visual acuity improved in 3 of 4 patients. In acute cystoid macular edema final visual acuity was 0.8-0.9, in chronic cystoid macular edema patient visual acuity improved from 0.05 to 0.2. In 3 of 4 patients central retinal thickness decreased and fovea anatomy was normalized. In patient with no clinical and anatomical improvement spectral optical coherence tomography examination revealed epiretinal membrane.
  
  
  CONCLUSIONS
  Intravitreal Avastin may be successful treatment in most Irvine-Gass syndrome cases. The condition that exclude patients from bevacizumab treatment is horizontal (epiretinal membrane), and vertical traction revealed in spectral optical coherence tomography.
authors.affiliation: Oddzial Okulistyki III Szpitala Miejskiego im. Karola Jonschera w Łodzi. bartek635@wp.pl
authors.forename: Bartosz
authors.initials: B
authors.lastname: Izdebski
authors.forename: Zofia
authors.initials: Z
authors.lastname: Michalewska
authors.forename: Krzysztof
authors.initials: K
authors.lastname: Dziegielewski
authors.forename: Jerzy
authors.initials: J
authors.lastname: Nawrocki
authors.forename: Dominik
authors.initials: D
authors.lastname: Odrobina
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D020533:Angiogenesis Inhibitors / Q000008:administration & dosage*; D061067:Antibodies, Monoclonal, Humanized / Q000008:administration & dosage*; D000068258:Bevacizumab; D005260:Female; D005451:Fluorescein Angiography; D006801:Humans; D058449:Intravitreal Injections; D008269:Macular Edema / Q000175:diagnosis / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D041623:Tomography, Optical Coherence; D016896:Treatment Outcome; D014792:Visual Acuity / Q000187:drug effects*
chemical_list: D020533:Angiogenesis Inhibitors; D061067:Antibodies, Monoclonal, Humanized; D000068258:Bevacizumab